Role of Inflammatory Markers in Sepsis

A diagnostic and prognostic study, in which the expression of CD64 in activated neutrophils and CD64 and IL17A regulatory T cells in patients with sepsis will be evaluated as a probable marker for sepsis as a primary objective

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diagnostic Disease Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Walaa Y Elsabeeny

Cairo, 11796, Egypt

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Cancer patients admitted to the surgical ICU following cancer related surgeries and diagnosed with sepsis

Exclusion criteria

Refusal of patient or patient guardian to participate.
Intraoperative massive blood loss and massive blood transfusion
Patients with impaired preoperative kidney or liver function tests

Treatment and study plan

Serology tests

Diagnostic Test

CD4, CD25, IL17

Primary outcomes

To evaluate the expression CD4

Time frame: 7 days

Serology
To evaluate the expression CD25

Time frame: 7 days

Serology
To evaluate the expression IL17

Time frame: 7 days

Serology

Sponsors and collaborators

Lead sponsor

National Cancer Institute, Egypt

Other

Registry information

Official study title

Role of Inflammatory Markers Measured Using Flow Cytometry in the Diagnosis and Prognosis of Sepsis in Surgical Cancer Patients

Important dates

Study start: 2023
Primary completion: 2025
Study completion: 2025
First posted: Nov 1, 2023
Registry last updated: Jul 16, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed